Member Info for sadoldgit

Very interesting post. Vaccinations are not the be all and end all. Most vaccinations consist of (with regards to viral protection) an inert ie dead cell or a weakened virus which the body then can develop vial its own immune system.
I can only deduce, that they have formulations added, and are not just the carrier of the weakened or inert virus but also other intentionally introduced inhibiting compounds.

I may be wrong as just my opinion on this.

Regards

With regards to the crystalline formation of a compound and its impending patent, Since Sareum have experienced formulation and solubility issues and I am advocating that this patent is far more than it initially appears.

I will explain. Should they have conquered the solubility issues (as similar compounds used in FLT+3) and a subsequent granting of patent for this crytallisation of a compound is granted, with the expectation of SDC1801 and 1802 being successful including the oral route ( that I firmly believe is the case), then effectively this provides protection for a period of 20 years from date of application ie last year and not when original patents were taken out for our 1802 and 1801 circa 2013 onwards. Compound is not covered as such, but just the manufacturing of hence a direct prevention of equivalent generic production of our compounds.

Views most welcome on this one.

Patent application to grant is around 18 months so thinking, Agile trial, granting of patent, then full scale production if and when the magnitude of success is established with our compounds.

Maybe Sareum can have manufacturing earlier using this crytallisation of a compound. As far as I know it is the normal procedure to have patent granted, then put into practice the area which the patent covers.

Regards.

Safetrader. On very little share volume price will tend to drift down especially when good news is anticipated. It has happened at Say for iast 10 years. That is myself answering myself as to why?

I would love to hear your views and theories on this and the information you rely on that forms the basis of your opinion s

Regards and have a super day.

of course we have as those that post here will already know combination of Jak1.
An excerpt follows which best read and understood and as far as I can see is the classic control of IL-6

Abstract
The shared cytokine receptor gp130 signals as a homodimer or heterodimer through activation of Janus kinases (Jaks) associated with the receptor intracellular domains. Here, we reconstitute, in parts and whole, the full-length gp130 homodimer in complex with the cytokine interleukin-6 (IL-6), its alpha receptor (IL-6Ra) and Jak1, for electron microscopy imaging. We find that the full-length gp130 homodimer complex has intimate interactions between the trans- and juxtamembrane segments of the two receptors, appearing to form a continuous connection between the extra- and intracellular regions. 2D averages and 3D reconstructions of full-length Jak1 reveal a three lobed structure comprising FERM-SH2, pseudokinase, and kinase modules possessing extensive intersegmental flexibility that likely facilitates allosteric activation. Single-particle imaging of the gp130/IL-6/IL-6Ra/Jak1 holocomplex shows Jak1 associated with the membrane proximal intracellular regions of gp130, abutting the would-be inner leaflet of the cell membrane. Jak1 association with gp130 is enhanced by the presence of a membrane environment.

Wow no more non classic disadvantage of the TyK 2 as the alternative signalling pathway covered by JAK1.

Surely it would be better to get hat an understanding that our TYK2 Jak1 inhibitor before persons prattle on about how much it is worth.

if it dont work there are no big bucks

Yes i do research completed my OU science degree 30 years ago. Bio chemistry and micro biology is not my specialised field. But I make an effort to learn even though getting on a bit.

My last post here so enjoy!

For those that know i apologise in advance.

Therefore, one way to block pathological IL-6 trans-signalling would be via TYK2 kinase-inhibition. Large pharmaceutical companies apparently have realized that selective TYK2 inhibition (vis-à-vis other kinases, in particular also to JAK1 and JAK2) may represent a worthwhile development target [161][162][163]. However, an obvious disadvantage of this approach is that it will also inhibit the desirable IL-6 classic signalling. .

Oh dear dear dear dear

Hi Ahfam, with regards to crystallisation of compounds. It is not new but in Sareums case may well be very novel.
A crystalline solid form or crystal exists when the molecules of the drug are arranged in the solid in a three-dimensional repeating pattern or unit cell . Crystalline solids are usually highly stable and have a well-established solubility and dissolution rate. Most drugs are used in the crystalline form.

Shall not be posting on here for a while as a bit tired of the dross.

Regards

SDC1801 superior to Demamaxathone and similar to Baricitinib. These relates to profile only. The proof of the pudding is in the eating so as to speak. SDC 1801 no to little toxicity even at very high levels. In this instance although the profile is similar due to the toxicity issues and restrictions placed on the emergency use of Baricitinib due to some serious side effects then by very definition Baricitinib is dreadfully inferior to SDC1801
Baricitinib not particularly good in areas of metabolism.
1801 has no Jak2 long associated with severe side effects and less selective than TyK2. Yes it contains Jak 1 but the molecular uptake is very similar to the Jak2
SDC has Jak 1 which can signal through different pathway and the Tyk2 has greater selectivity over Jak1. Baricitinib not even fit tobe in the same room
Regards

I cannot see what benefit apart from the financial gains to the pharma that produce this inhibitor to a sufferer from Covid 19. It truly is a desperate measure. Recommendation were made by the WHO in Nov 2020 against its use.

https://www.rxwiki.com/olumiant

Complete and under disregard for others health and safety, They dont believe Covid is a real threat. They also think well it aint going to affect me so why should I were a mask. I got my rights. So what if a few old people die.

True there are people who do not show symptoms but the stronger your immune system the more likely you are to develop severe problems. Oddly very little effect on HIV infected people. These people just become mutation factories.

Lambda variant been out a while and will quickly establish itself.

Regards

How much money is the pharmaceutical industry worth?
How much is the pharmaceutical industry worth? The global pharmaceutical industry was worth $934.8 billion in 2017 and will reach $1170 billion in 2021, growing at 5.8%. Current estimates that global pharma spending will exceed USD 1.5 trillion by 2023.

Plenty of room for 1801, 1802 and 737.

Market cap at the bottom according to LSE shows a decent amount. I think Thoth must of had a word with them.

Open 6.65
P/E -
Vol 19.56 M
High 6.70
52wk High 9.57
Avg Vol -
Low 6.70
52wk Low 0.50
Mkt Cap 22.16 B

Potnak. My feeling is the government will be aware of potential new treatments. They have provided Agile funding. The secrecy now cannot be kept water tight as people outside of Sareum will know ie government researchers/ officials. Speculation will eventually be replaced by factual results. I would love to know the state of play with regards to Sareum and the interested parties they have been in discussions with over the past few years. How many new parties are in discussion?

Next news due is entry to AGILE confirmation. There will be now as we chat people outside this board and outside of Sareum that will know this. It is of no surprise that I find large buys coming in. Many more will be following soon.

The government must have a contingency plan with regards to Covid 19 taking a turn for the worse ( very likely I fee). There is very little out there that has the pedigree of SDC1801 of that I am firmly of the belief.

Perhaps Hanky panky Han....k has put his pay off to good use. ( Only joking)

On a more serious note it should not be long before we hear news of SRA737. They will be required to either commit to furthering research or hand back. I am of the opinion that the former will happen.

It is still a waiting game. Waited 9 years not as long as some I might add. But a few weeks and that ought to indicate just where the Sareum market cap is heading.

Regards and beer time for me.

Good evening desamax. Apologies late getting back. I take it you are referring to the following

Dr John Reader, CSO of Sareum, commented:

"The results from our Covid-19 research project are very encouraging and provide clear evidence of the potential of SDC-1801 to reduce the excessive inflammatory response seen in severe Covid-19. We are keen to progress this project to the next stage and will now explore our options to find the best way to fund these next steps. This could include the UK government's AGILE clinical development platform, which was established to fund Phase 1 trials and fast-track the development of potentially ground-breaking Covid-19 treatments. These activities are expected to run in parallel with the broader SDC-1801 development plan targeting autoimmune diseases. We look forward to providing updates on our progress as we reach key milestones in the development of SDC-1801."

'The results from the research are encouraging' indicative of favourable results I would say. Need be careful with wording.
'and providing clear evidence of the potential' this will be from models, mostly murine but these models becoming very precise predicting success. It will come down to human trials, If we take CHK1 as an example our compound again had excellent ADME ie absorption, distribution. metabolism and excretion results. proved also in stage 1 plus trials.

Sareum cannot make a statement such as it works as has not been put into trials yet. It is not 100% certain. For them to state that it will be successful would be unfair to the investor and also open themselves up to litigation.

However in light of this, my opinion it has been worded in such a way as to almost and I repeat that almost guaranteed success. It will I strongly believe easily outperform Baricitinib as not tied on dose restriction due to virtually zero toxicity issues.
With regards to best way of funding as opposed to the only way of funding would indicate to me there are interested parties wishing to participate in financing further and advancing SDC1801 into trials. There does still remain without doubt the eligibility to gain acceptance to Agile platform.

It is as near as Sareum can get to entering Agile without them stating it directly. More implied than stated. They have chosen the wording very wisely.

Regards and again my breakdown of.

Interestingly worded abstract from RNS.

'The project has completed on schedule, with the final results confirming the initial encouraging results as noted in the Company's Interim Results, published on 23 April 2021. The results of the project found that SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib, a JAK1/JAK2 inhibitor.

Profile I am taking as an overview in that of aim of the objectives.
Tim can say no more on this as trials in humans have not yet started. It therefore can only be compared when trials start.
We have far superior safety as being a TYK2 inhibitor and more selective than Jak2.
In investigations so far it has been remarked of the down regulation of the cytokine storm( dose dependant too with no to little toxicity) even at high dosage rates.
Effectiveness will be established once trials in human beings. It remains to be seen just how effective SDC1801 is. All in all looking good and as i see it will be streets ahead of Baricitinib.

My interpretation and opinion on this.

Regards all and have a great weekend

No problems. It does annoy me a little when a subject goes up that can mislead people. Excessive ramping and deramping not much different here.

All looks good as l see it and a good kick North with the SP on news of Agile. It should not be a problem as even if performed equal to baricitinib it still has a far better safety profile.

Tyk 2 Jak1 much better than jak 1, jak2.

It is not a bad idea to look through some of the interviews of Tim Mitchell by Andrew Scott the smooth talking Aussie with regards getting to know about our compounds.

Regards and welcome aboard here. There are some great posters on here.

No problems. It does annoy me a little when a subject goes up that can mislead people. Excessive ramping and deramping not much different here.

All looks good as l see it and a good kick North with the SP on news of Agile. It should not be a problem as even if performed equal to baricitinib it still has a far better safety profile.

Tyk 2 Jak1 much better than jak 1, jak2.

It is not a bad idea to look through some of the interviews of Tim Mitchell by Andrew Scott the smooth talking Aussie with regards getting to know about our compounds.

Regards and welcome aboard here. There are some great posters on here.

Veody. I know it does not stipulate timescales
It was however in someone's opinion that the entry into Agile would be a minimum of 4 weeks. Under a heading Minimum of 4 weeks to Agile. Very misleading for someone one who has taken recent interest.

Regards

Pred text. Womble not Wimbledon and chancers not chances.

The Senekot 5cheitehostess more appropriate for them two chances.

Not long to go now. Wimbledon day next Monday start.

Regards

Subject implies minimum of 4 weeks to Agile RNS which is totally unsubstantiated.

Regards